查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1233089

神經病學臨床試驗市場規模,份額和趨勢分析:按階段(第一,第二),研究設計(介入),適應症,地區,市場預測,2022-2030

Neurology Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II), By Study Design (Interventional), By Indication, By Region, And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

神經學臨床試驗市場增長和趨勢

Grand View Research, Inc. 的一份新報告顯示，2023 年至 2030 年，全球神經病學臨床試驗市場規模的年復合增長率將達到 5.6%，到 □□2030 年將達到 80 億5290萬美元。

這是由於各大製藥公司在神經科學領域開展創新臨床試驗，增加政府對國家神經疾病和中風研究所 (NINDS) 的資助，以及全球範圍內神經系統疾病的流行率高是主要原因。

神經科學繼續獲得穩健的投資。 例如，2022 年 11 月，NRG Therapeutics 宣布獲得 1830 萬美元的 A 輪融資，用於開發治療肌萎縮側索硬化症（ALS）和帕金森病等神經退行性疾□□病的線粒體療法。 預計未來類似舉措的採用將支持市場的增長。

在世界範圍內，有相當多的人患有神經系統疾病。 例如，據帕金森基金會統計，每年有 6 萬美國人被診斷患有帕金森病，全世界有超過 1000 萬人患有這種疾病。 據世界衛生組織稱，全世界有超過 6500 萬人患有癲癇症。 該病在低收入和中等收入國家最為常見，佔癲癇患者的80.0%。預計神經系統疾病的高患病率將推動對臨床試驗的需求並支持市場。

神經病學被認為是進行臨床試驗的主要領域之一。 根據醫藥研發年度回顧，2021年，神經病學試驗將成為臨床試驗的第三大重點。 根據《醫藥研發年度回顧》，神經內科臨床試驗藥物超過2900種，到2022年，神經內科臨床試驗活性藥物將超過3200種。 進入神經病學臨床試驗的藥物的增加預計將在大流行後時期支持市場。

神經病學臨床試驗市場報告要點。

  • 二期細分市場佔據市場主導地位，在 2022 年佔最大收入份額，達到 46.3%。 大多數神經病學臨床試驗目前處於支持該細分市場的第 2 階段。
  • 到 2022 年，介入細分市場的收入份額最大，達到 96.1%。 使用這種試驗設計類型進行的大量神經學臨床試驗正在推動這一細分市場的增長。
  • 亨廷頓氏舞蹈症領域預計在預測期內實現最快的複合年增長率 6.0%。 這主要是由於全世界對用於治療亨廷頓舞蹈病的藥物的需求量很大，因為沒有可用於治療它的藥物。
  • 北美在市場中佔據主導地位，2022 年佔收入份額的 47.0%。 神經系統疾病患病率的上升和臨床試驗中眾多參與者的出現正在推動該地區的市場。 這些是其高市場份額的一些主要原因。

內容

第 1 章調查方法及範圍

  • 市場細分和範圍
    • 階段
    • 研究設計
    • 展示
    • 研究設計的適應症
    • 按階段顯示
  • 調查方法
  • 資訊採購
    • 購買的數據庫
    • GVR 內部數據庫
    • 次要資訊
    • 初步調查
    • 初步調查的內容
  • 資訊或數據分析
    • 數據分析模型
  • 市場製定和驗證
  • 模型詳細資訊
    • 商品流分析（模型1）
      • 方法 1：商品流方法
    • 批量價格分析（模型2）
      • 方法 2：體積分析
  • 二級資訊列表
  • 主要資訊列表
  • 目的

第 2 章執行摘要

  • 市場展望

第 3 章神經病學臨床試驗市場變量、趨勢和範圍

  • 市場系列展望
    • 母公司市場展望
    • 相關/子公司市場前景
  • 描繪採用情況和增長前景
  • 市場動態
    • 市場促進因素分析
      • 阿爾茨海默病、癲癇和中風等神經系統疾病的患病率增加
      • 在臨床研究中更多地採用新技術
      • 許多提供神經病學臨床研究服務的 CRO
      • 增加公共機構對神經學研究的資助
    • 市場抑制因素分析
      • 與神經學臨床研究相關的高成本
      • 高失敗率加上與神經臨床試驗相關的患者退出問題
  • 神經臨床試驗市場分析工具
    • 波特的五力分析
    • PEST分析
  • COVID-19 的影響和改革戰略

第 4 章神經病學臨床試驗市場：階段估計和趨勢分析

  • 定義和範圍
  • 神經臨床試驗市場：階段市場份額分析，2022 年和 2030 年
    • 第一階段
    • 第二階段
    • 第三階段
    • 第四階段

第 5 章神經病學臨床試驗市場：研究設計估計和趨勢分析

  • 定義和範圍
  • 神經臨床試驗市場：研究設計市場份額分析，2022 年和 2030 年
    • 干預
    • 觀察性的
    • 擴大訪問範圍

第 6 章神經病學臨床試驗市場：適應症估計和估計/趨勢分析

  • 定義和範圍
  • 神經臨床試驗市場：適應症市場份額分析，2022 年和 2030 年
    • 癲癇症
    • 帕金森病 (PD)
    • 亨廷頓舞蹈症
    • 中風
    • 創傷性腦損傷 (TBI)
    • 肌萎縮側索硬化 (ALS)
    • 肌肉再生
    • 其他

第 7 章神經病學臨床試驗市場：研究設計估計和趨勢分析的適應症

  • 定義和範圍
  • 神經臨床試驗市場：按研究設計進行的適應症市場份額分析，2022 年和 2030 年
    • 癲癇症
      • 干預
      • 觀察性的
      • 擴大訪問範圍
    • 帕金森病 (PD)
      • 干預
      • 觀察性的
      • 擴大訪問範圍
    • 亨廷頓舞蹈症
      • 干預
      • 觀察性的
      • 擴大訪問範圍
    • 中風
      • 干預
      • 觀察性的
      • 擴大訪問範圍
    • 創傷性腦損傷 (TBI)
      • 干預
      • 觀察性的
      • 擴大訪問範圍
    • 肌萎縮側索硬化 (ALS)
      • 干預
      • 觀察性的
      • 擴大訪問範圍
    • 肌肉再生
      • 干預
      • 觀察性的
      • 擴大訪問範圍
    • 其他
      • 干預
      • 觀察性的
      • 擴大訪問範圍

第 8 章神經病學臨床試驗市場：階段估計和趨勢分析的適應症

  • 定義和範圍
  • 神經臨床試驗市場：分級適應症市場份額分析，2022 年和 2030 年
    • 癲癇症
      • 第一階段
      • 第二階段
      • 第三階段
      • 第四階段
    • 帕金森病 (PD)
      • 第一階段
      • 第二階段
      • 第三階段
      • 第四階段
    • 亨廷頓舞蹈症
      • 第一階段
      • 第二階段
      • 第三階段
      • 第四階段
    • 中風
      • 第一階段
      • 第二階段
      • 第三階段
      • 第四階段
    • 創傷性腦損傷 (TBI)
      • 第一階段
      • 第二階段
      • 第三階段
      • 第四階段
    • 肌萎縮側索硬化 (ALS)
      • 第一階段
      • 第二階段
      • 第三階段
      • 第四階段
    • 肌肉再生
      • 第一階段
      • 第二階段
      • 第三階段
      • 第四階段
    • 其他
      • 第一階段
      • 第二階段
      • 第三階段
      • 第四階段

第 9 章神經病學臨床試驗市場：區域估計和趨勢分析

  • 2022 年和 2030 年區域市場份額分析
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 意大利
    • 西班牙
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
  • 多邊環境協定
    • 南非
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國

第 10 章競爭格局

  • 市場份額分析
  • 參與公司
  • 近期發展和影響分析

第 11 章公司簡介

  • 公司概況
  • 財務業績
  • 戰略舉措
    • 分機
    • 夥伴關係和協作
    • 收購
      • Novartis
      • Covance
      • Med pace
      • Charles River Laboratories
      • Syneous Health
      • Icon Plc
      • GlaxoSmithKline
      • Aurora healthcare
      • Biogen
      • IQVIA
Product Code: GVR-4-68038-352-2

Neurology Clinical Trials Market Growth & Trends:

The global neurology clinical trials market size is expected to reach USD 8,052.9 million by 2030, registering a CAGR of 5.6% from 2023 to 2030, according to a new report by Grand View Research, Inc. This is largely attributed to big pharma companies conducting innovative trials in neurology, increased government funding from the National Institute of Neurological Disorders and Stroke (NINDS), and the high prevalence of neurological disorders worldwide.

Neuroscience continues to receive a healthy investment. For instance, in November 2022, NRG Therapeutics raised Series A funding of USD 18.3 million for the development of mitochondrial therapeutics to treat neurodegenerative ailments such as amyotrophic lateral sclerosis (ALS) and Parkinson's disease. The adoption of similar initiatives in the future is expected to support market growth.

A significant number of people worldwide suffer from neurological disorders. For instance, as per the statistics from Parkinson's Foundation, every year 60,000 Americans are diagnosed with PD and more than 10 million people are living with the disease around the world. In terms of Epilepsy, the WHO states that more than 65 million people worldwide are affected by it. The disease is most prevalent in low- and middle-income countries, which account for 80.0% of epilepsy cases. A high prevalence of neurological disorders is expected to boost demand for clinical trials and thus support the market.

Neurology is considered as one of the major areas where clinical trials are conducted. As per the Pharma R&D Annual Review, in 2021, Neurology trials were the third area where clinical trials were majorly focused. The Pharma R&D Annual Review stated that for neurology above 2,900 drugs were under trial and in the year 2022 the number of drugs for clinical studies in the area of neurology accounted for more than 3,200 active drugs. An increasing number of drugs entering clinical trials in the area of neurology are expected to support the market in the post-pandemic period.

Neurology Clinical Trials Market Report Highlights:

  • The phase II segment dominated the market and accounted for a maximum revenue share of 46.3% in 2022. A majority number of neurology clinical trials are currently in Phase 2, this is supporting the segment market
  • The interventional segment held the largest market revenue share of 96.1% in 2022. A high number of neurology clinical trials conducted through this study design type is promoting the growth of the segment market
  • The Huntington's disease segment is anticipated to register the fastest CAGR of 6.0% during the forecast period. This is largely due to the fact that there is a high demand for the medicines used for Huntington's disease worldwide as there are no medications available for treating this disease
  • North America dominated the market and accounted for a revenue share of 47.0% in 2022. The rising prevalence of neurological disorders and the presence of a large number of players in clinical trials drive the market in the region. These are some of the key reasons for the high market share

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Phase
    • 1.1.2. Study Design
    • 1.1.3. Indication
    • 1.1.4. Indication by Study Design
    • 1.1.5. Indication by Phase
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
    • 1.6.2. Volume price analysis (Model 2)
      • 1.6.2.1. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook

Chapter 3. Neurology Clinical Trials Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & growth prospect mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
      • 3.3.1.1. Increasing prevalence of neurological diseases such as Alzheimer disease, epilepsy, and stroke
      • 3.3.1.2. Growing adoption of novel technologies in clinical research
      • 3.3.1.3. Significant number of CROs providing neurology clinical research services
      • 3.3.1.4. Increasing funding for neurological studies by public organizations
    • 3.3.2. Market restraint analysis
      • 3.3.2.1. High cost associated with neurology clinical studies.
      • 3.3.2.2. High failure rate coupled with patient dropout issues associated with neurological clinical trials.
  • 3.4. Neurology Clinical Trials Market Analysis Tools
    • 3.4.1. Porter's Five Forces Analysis
    • 3.4.2. PEST Analysis
  • 3.5. COVID-19 Impact and Reformation Strategy

Chapter 4. Neurology Clinical Trials Market: Phase Estimates & Trend Analysis

  • 4.1. Definitions and Scope
  • 4.2. Neurology Clinical Trials Market: Phase Market Share Analysis, 2022 & 2030
    • 4.2.1. Phase I
    • 4.2.2. Phase II
    • 4.2.3. Phase III
    • 4.2.4. Phase IV

Chapter 5. Neurology Clinical Trials Market: Study Design Estimates & Trend Analysis

  • 5.1. Definitions and Scope
  • 5.2. Neurology Clinical Trials Market: Study Design Market Share Analysis, 2022 & 2030
    • 5.2.1. Interventional
    • 5.2.2. Observational
    • 5.2.3. Expanded Access

Chapter 6. Neurology Clinical Trials Market: Indication Estimates & Trend Analysis

  • 6.1. Definitions and Scope
  • 6.2. Neurology Clinical Trials Market: Indication Market Share Analysis, 2022 & 2030
    • 6.2.1. Epilepsy
    • 6.2.2. Parkinson's Disease (PD)
    • 6.2.3. Huntington's Disease
    • 6.2.4. Stroke
    • 6.2.5. Traumatic Brain Injury (TBI)
    • 6.2.6. Amyotrophic Lateral Sclerosis (ALS)
    • 6.2.7. Muscle regeneration
    • 6.2.8. Others

Chapter 7. Neurology Clinical Trials Market: Indication By Study Design Estimates & Trend Analysis

  • 7.1. Definitions and Scope
  • 7.2. Neurology Clinical Trials Market: Indication By Study Design Market Share Analysis, 2022 & 2030
    • 7.2.1. Epilepsy
      • 7.2.1.1. Interventional
      • 7.2.1.2. Observational
      • 7.2.1.3. Expanded Access
    • 7.2.2. Parkinson's Disease (PD)
      • 7.2.2.1. Interventional
      • 7.2.2.2. Observational
      • 7.2.2.3. Expanded Access
    • 7.2.3. Huntington's Disease
      • 7.2.3.1. Interventional
      • 7.2.3.2. Observational
      • 7.2.3.3. Expanded Access
    • 7.2.4. Stroke
      • 7.2.4.1. Interventional
      • 7.2.4.2. Observational
      • 7.2.4.3. Expanded Access
    • 7.2.5. Traumatic Brain Injury (TBI)
      • 7.2.5.1. Interventional
      • 7.2.5.2. Observational
      • 7.2.5.3. Expanded Access
    • 7.2.6. Amyotrophic Lateral Sclerosis (ALS)
      • 7.2.6.1. Interventional
      • 7.2.6.2. Observational
      • 7.2.6.3. Expanded Access
    • 7.2.7. Muscle regeneration
      • 7.2.7.1. Interventional
      • 7.2.7.2. Observational
      • 7.2.7.3. Expanded Access
    • 7.2.8. Others
      • 7.2.8.1. Interventional
      • 7.2.8.2. Observational
      • 7.2.8.3. Expanded Access

Chapter 8. Neurology Clinical Trials Market: Indication By Phase Estimates & Trend Analysis

  • 8.1. Definitions and Scope
  • 8.2. Neurology Clinical Trials Market: Indication By Phase Market Share Analysis, 2022 & 2030
    • 8.2.1. Epilepsy
      • 8.2.1.1. Phase I
      • 8.2.1.2. Phase II
      • 8.2.1.3. Phase III
      • 8.2.1.4. Phase IV
    • 8.2.2. Parkinson's Disease (PD)
      • 8.2.2.1. Phase I
      • 8.2.2.2. Phase II
      • 8.2.2.3. Phase III
      • 8.2.2.4. Phase IV
    • 8.2.3. Huntington's Disease
      • 8.2.3.1. Phase I
      • 8.2.3.2. Phase II
      • 8.2.3.3. Phase III
      • 8.2.3.4. Phase IV
    • 8.2.4. Stroke
      • 8.2.4.1. Phase I
      • 8.2.4.2. Phase II
      • 8.2.4.3. Phase III
      • 8.2.4.4. Phase IV
    • 8.2.5. Traumatic Brain Injury (TBI)
      • 8.2.5.1. Phase I
      • 8.2.5.2. Phase II
      • 8.2.5.3. Phase III
      • 8.2.5.4. Phase IV
    • 8.2.6. Amyotrophic Lateral Sclerosis (ALS)
      • 8.2.6.1. Phase I
      • 8.2.6.2. Phase II
      • 8.2.6.3. Phase III
      • 8.2.6.4. Phase IV
    • 8.2.7. Muscle regeneration
      • 8.2.7.1. Phase I
      • 8.2.7.2. Phase II
      • 8.2.7.3. Phase III
      • 8.2.7.4. Phase IV
    • 8.2.8. Others
      • 8.2.8.1. Phase I
      • 8.2.8.2. Phase II
      • 8.2.8.3. Phase III
      • 8.2.8.4. Phase IV

Chapter 9. Neurology Clinical Trials Market: Regional Estimates & Trend Analysis

  • 9.1. Regional market share analysis, 2022 & 2030
  • 9.2. North America
    • 9.2.1. U.S.
      • 9.2.1.1. U.S. market estimates and forecast, 2018-2030
    • 9.2.2. Canada
      • 9.2.2.1. Canada market estimates and forecast, 2018-2030
  • 9.3. Europe
    • 9.3.1. U.K.
      • 9.3.1.1. U.K. market estimates and forecast, 2018-2030
    • 9.3.2. Germany
      • 9.3.2.1. Germany market estimates and forecast, 2018-2030
    • 9.3.3. France
      • 9.3.3.1. France market estimates and forecast, 2018-2030
    • 9.3.4. Italy
      • 9.3.4.1. Italy market estimates and forecast, 2018-2030
    • 9.3.5. Spain
      • 9.3.5.1. Spain market estimates and forecast, 2018-2030
  • 9.4. Asia Pacific
    • 9.4.1. Japan
      • 9.4.1.1. Japan market estimates and forecast, 2018-2030
    • 9.4.2. China
      • 9.4.2.1. China market estimates and forecast, 2018-2030
    • 9.4.3. India
      • 9.4.3.1. India market estimates and forecast, 2018-2030
    • 9.4.4. Australia
      • 9.4.4.1. Australia market estimates and forecast, 2018-2030
    • 9.4.5. South Korea
      • 9.4.5.1. South Korea market estimates and forecast, 2018-2030
  • 9.5. Latin America
    • 9.5.1. Brazil
      • 9.5.1.1. Brazil market estimates and forecast, 2018-2030
    • 9.5.2. Mexico
      • 9.5.2.1. Mexico market estimates and forecast, 2018-2030
    • 9.5.3. Argentina
      • 9.5.3.1. Argentina market estimates and forecast, 2018-2030
    • 9.5.4. Colombia
      • 9.5.4.1. Colombia market estimates and forecast, 2018-2030
  • 9.6. MEA
    • 9.6.1. South Africa
      • 9.6.1.1. South Africa market estimates and forecast, 2018-2030
    • 9.6.2. Saudi Arabia
      • 9.6.2.1. Saudi Arabia market estimates and forecast, 2018-2030
    • 9.6.3. UAE
      • 9.6.3.1. UAE market estimates and forecast, 2018-2030

Chapter 10. Competitive Landscape

  • 10.1. Market Share Analysis
  • 10.2. Participant Categorization
  • 10.3. Recent Development and Impact Analysis

Chapter 11. Company Profiles

  • 11.1. Company Overview
  • 11.2. Financial Performance
  • 11.3. Strategic Initiatives
    • 11.3.1. Expansions
    • 11.3.2. Partnerships and Collaborations
    • 11.3.3. Acquisitions
      • 11.3.3.1. Novartis
      • 11.3.3.2. Covance
      • 11.3.3.3. Med pace
      • 11.3.3.4. Charles River Laboratories
      • 11.3.3.5. Syneous Health
      • 11.3.3.6. Icon Plc
      • 11.3.3.7. GlaxoSmithKline
      • 11.3.3.8. Aurora healthcare
      • 11.3.3.9. Biogen
      • 11.3.3.10. IQVIA

List of Tables

  • TABLE 1 List of secondary sources
  • TABLE 2 List of Abbreviations

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information Procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modelling for market share assessment
  • FIG. 7 Market segmentation & scope
  • FIG. 8 Neurology Clinical Trials market outlook, 2018 - 2030
  • FIG. 9 Market trends & outlook
  • FIG. 10 Market driver relevance analysis (Current & future impact)
  • FIG. 11 Market restraint relevance analysis (Current & future impact)
  • FIG. 12 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 13 Porter's Five Forces Analysis
  • FIG. 14 Neurology Clinical Trials market : Phase outlook key takeaways
  • FIG. 15 Neurology Clinical Trials market : Phase movement analysis
  • FIG. 16 Active Pharmaceutical Ingredients (API) market, 2018 - 2030 (USD Million)
  • FIG. 17 Phase I market, 2018 - 2030 (USD Million)
  • FIG. 18 Phase II market, 2018 - 2030 (USD Million)"
  • FIG. 19 Phase III market, 2018 - 2030"
  • FIG. 20 Phase IV market, 2018 - 2030 (USD Million)
  • FIG. 21 Neurology Clinical Trials market : Indication outlook key takeaways
  • FIG. 22 Neurology Clinical Trials market : Indication movement analysis
  • FIG. 23 Epilepsy market, 2018 - 2030
  • FIG. 24 Parkinson's Disease (PD) market, 2018 - 2030 (USD Million)
  • FIG. 25 Huntington's Disease market, 2018 - 2030 (USD Million)
  • FIG. 26 Stroke market, 2018 - 2030 (USD Million)
  • FIG. 27 Traumatic Brain Injury (TBI) market, 2018 - 2030 (USD Million)
  • FIG. 28 Stroke market, 2018 - 2030 (USD Million)
  • FIG. 29 Amyotrophic Lateral Sclerosis (ALS) market, 2018 - 2030 (USD Million)
  • FIG. 30 Muscle regeneration market, 2018 - 2030 (USD Million)
  • FIG. 31 Others market, 2018 - 2030 (USD Million)
  • FIG. 32 Neurology Clinical Trials market: Study Design outlook key takeaways
  • FIG. 33 Neurology Clinical Trials market: Study Design movement analysis
  • FIG. 34 Interventional market, 2018 - 2030 (USD Million)
  • FIG. 35 Observational market, 2018 - 2030 (USD Million)
  • FIG. 36 Expanded Access, 2018 - 2030 (USD Million)
  • FIG. 37 Neurology Clinical Trials market: Indication by Study Design outlook key takeaways
  • FIG. 38 Neurology Clinical Trials market: Indication by Study Design movement analysis
  • FIG. 39 Epilepsy interventional studies market, 2018 - 2030 (USD Million)
  • FIG. 40 Epilepsy observational studies market, 2018 - 2030 (USD Million)
  • FIG. 41 Epilepsy expanded acess studies market, 2018 - 2030 (USD Million)
  • FIG. 42 Parkinson's Disease (PD) interventional studies market, 2018 - 2030 (USD Million)
  • FIG. 43 Parkinson's Disease (PD) observational studies market, 2018 - 2030 (USD Million)
  • FIG. 44 Parkinson's Disease (PD) expanded acess studies market, 2018 - 2030 (USD Million)
  • FIG. 45 Huntington's Disease interventional studies market, 2018 - 2030 (USD Million)
  • FIG. 46 Huntington's Diseaseobservational studies market, 2018 - 2030 (USD Million)
  • FIG. 47 Huntington's Disease expanded acess studies market, 2018 - 2030 (USD Million)
  • FIG. 48 Stroke interventional studies market, 2018 - 2030 (USD Million)
  • FIG. 49 Stroke observational studies market, 2018 - 2030 (USD Million)
  • FIG. 50 Stroke expanded acess studies market, 2018 - 2030 (USD Million)
  • FIG. 51 Traumatic Brain Injury (TBI) interventional studies market, 2018 - 2030 (USD Million)
  • FIG. 52 Traumatic Brain Injury (TBI) observational studies market, 2018 - 2030 (USD Million)
  • FIG. 53 Traumatic Brain Injury (TBI) expanded acess studies market, 2018 - 2030 (USD Million)
  • FIG. 54 Amyotrophic Lateral Sclerosis (ALS) interventional studies market, 2018 - 2030 (USD Million)
  • FIG. 55 Amyotrophic Lateral Sclerosis (ALS) observational studies market, 2018 - 2030 (USD Million)
  • FIG. 56 Amyotrophic Lateral Sclerosis (ALS) expanded acess studies market, 2018 - 2030 (USD Million)
  • FIG. 57 Muscle regeneration interventional studies market, 2018 - 2030 (USD Million)
  • FIG. 58 Muscle regeneration observational studies market, 2018 - 2030 (USD Million)
  • FIG. 59 Muscle regeneration expanded acess studies market, 2018 - 2030 (USD Million)
  • FIG. 60 Others interventional studies market, 2018 - 2030 (USD Million)
  • FIG. 61 Others observational studies market, 2018 - 2030 (USD Million)
  • FIG. 62 Others expanded acess studies market, 2018 - 2030 (USD Million)
  • FIG. 63 Neurology Clinical Trials market: Indication by Phase outlook key takeaways
  • FIG. 64 Neurology Clinical Trials market: Indication by Phase movement analysis
  • FIG. 65 "Epilepsy Phase I market, 2018 - 2030 (USD Million)"
  • FIG. 66 Epilepsy Phase II market, 2018 - 2030 (USD Million)
  • FIG. 67 Epilepsy Phase III market, 2018 - 2030 (USD Million)
  • FIG. 68 Epilepsy Phase IV market, 2018 - 2030 (USD Million)
  • FIG. 69 Parkinson's Disease (PD) Phase I market, 2018 - 2030 (USD Million)
  • FIG. 70 Parkinson's Disease (PD) Phase II market, 2018 - 2030 (USD Million)
  • FIG. 71 Parkinson's Disease (PD) Phase III market, 2018 - 2030 (USD Million)
  • FIG. 72 Parkinson's Disease (PD) Phase IV market, 2018 - 2030 (USD Million)
  • FIG. 73 Huntington's Disease Phase I market, 2018 - 2030 (USD Million)
  • FIG. 74 Huntington's Disease Phase II market, 2018 - 2030 (USD Million)
  • FIG. 75 Huntington's Disease Phase III market, 2018 - 2030 (USD Million)
  • FIG. 76 Huntington's Disease Phase IV market, 2018 - 2030 (USD Million)
  • FIG. 77 Stroke Phase I market, 2018 - 2030 (USD Million)
  • FIG. 78 Stroke Phase II market, 2018 - 2030 (USD Million)
  • FIG. 79 Stroke Phase III market, 2018 - 2030 (USD Million)
  • FIG. 80 Stroke Phase IV market, 2018 - 2030 (USD Million)
  • FIG. 81 Traumatic Brain Injury (TBI) Phase I market, 2018 - 2030 (USD Million)
  • FIG. 82 Traumatic Brain Injury (TBI) Phase II market, 2018 - 2030 (USD Million)
  • FIG. 83 Traumatic Brain Injury (TBI) Phase III market, 2018 - 2030 (USD Million)
  • FIG. 84 Traumatic Brain Injury (TBI) Phase IV market, 2018 - 2030 (USD Million)
  • FIG. 85 Amyotrophic Lateral Sclerosis (ALS)Phase I market, 2018 - 2030 (USD Million)
  • FIG. 86 Amyotrophic Lateral Sclerosis (ALS) Phase II market, 2018 - 2030 (USD Million)
  • FIG. 87 Amyotrophic Lateral Sclerosis (ALS) Phase III market, 2018 - 2030 (USD Million)
  • FIG. 88 Amyotrophic Lateral Sclerosis (ALS) Phase IV market, 2018 - 2030 (USD Million)
  • FIG. 89 Muscle regeneration Phase I market, 2018 - 2030 (USD Million)
  • FIG. 90 Muscle regeneration Phase II market, 2018 - 2030 (USD Million)
  • FIG. 91 Muscle regeneration Phase III market, 2018 - 2030 (USD Million)
  • FIG. 92 Muscle regeneration Phase IV market, 2018 - 2030 (USD Million)
  • FIG. 93 Others Phase I market, 2018 - 2030 (USD Million)
  • FIG. 94 Others Phase II market, 2018 - 2030 (USD Million)
  • FIG. 95 Others Phase III market, 2018 - 2030 (USD Million)
  • FIG. 96 Others Phase IV market, 2018 - 2030 (USD Million)
  • FIG. 97 Regional market place: Key takeaway
  • FIG. 98 Neurology Clinical Trials regional outlook, 2020 & 2028
  • FIG. 99 North America Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 100 U.S. Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 101 Canada Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 102 Europe Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 103 Germany Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 104 France Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 105 U.K. Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 106 Spain Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 107 Italy Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 108 Asia Pacific Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 109 Japan Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 110 India Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 111 China Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 112 South Korea Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 113 Australia Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 114 Latin America Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 115 Brazil Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 116 Mexico Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 117 Argentina Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 118 Colombia Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 119 Middle East & Africa Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 120 South Africa Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 121 Saudi Arabia Neurology Clinical Trials market, 2018 - 2030 (USD Million)
  • FIG. 122 UAE Neurology Clinical Trials market, 2018 - 2030 (USD Million)